Compare Illumina, Inc. (ILMN) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Medpace Holdings Inc — how do they compare? Illumina, Inc. trades at $192.7 (market cap $27.94B), while Medpace Holdings Inc trades at $530.22 (market cap $15.08B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Illumina, Inc. is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | MEDP | |
|---|---|---|
Market Cap | $27.94B | $15.08B |
Sector | Health | Technology |
52-Week High | $194.33 | $620.59 |
52-Week Low | $91.00 | $308.88 |
Enterprise Value | $29.33B | $14.55B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
